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To the Editors: Rosenkranz and colleagues report reassuringly high success rates for breast conserving 
surgery (BCS) in women with multiple ipsilateral breast cancers (MIBC)1. Surgical management of 
MIBC can pose a dilemma when more sensitive imaging modalities detect additional tumor foci that are 
potentially amenable to adaptive forms of BCS employing oncoplastic techniques2. Interestingly, there 
was minimal use of therapeutic mammoplasty amongst these patients, the majority of whom had two 
tumors (96%) separated by at least 2cm with the largest focus measuring ≤15mm1. Despite this highly 
selected group, more than 80% underwent standard BCS without tissue rearrangement and three-
quarters of all conservation patients achieved clear margins with a single operation1. There is potential 
for resection of larger T2 multicentric cancers in the Z11102 trial using more advanced oncoplastic 
surgery such as level II mammoplasties1,2. Furthermore, larger tumors are more likely to require a boost 
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dose and there are concerns about adverse effects from a double radiotherapy boost following BCS for 
MIBC2,3. There is limited data from phantom studies on relative positioning and delivery of two separate 
boosts2,3. Despite a median largest tumor size of 15mm, these patients received a boost to each tumor 
bed (10 - 16 Gy) that could lead to severe fibrosis with an estimated 10% increase in volume of breast 
tissue exposed to >60Gy3.   
 
Although there is lack of high quality comparative data from randomised or prospective cohort studies, a 
degree of surgical equipoise exists which prompted the latest St Gallen consensus to endorse BCS for 
some cases of MIBC4. In a systematic review involving 24 retrospective studies, only 6 compared rates 
of loco-regional recurrence (LRR) for BCS versus mastectomy2, with rates of LRR ranging from 2 – 
23% after BCS. Formal meta-analysis showed homogeneity amongst studies with equivalent rates of 
LRR irrespective of surgical procedure [risk ratio 0.94; 95% CI 0.65 – 1.36] 2. This may have partly 
reflected a similar case selection bias with surgeons choosing BCS for low risk patients and mastectomy 
for higher risk cases. Such confounding would lead to inconclusive results in terms of safety and clinical 
outcomes of BCS compared with mastectomy for MIBC.  
 
A survey of UK surgeons confirmed that 90% supported a randomised trial evaluating the efficacy of 
BCS compared with mastectomy (+/- reconstruction) for MIBC2,5. The MIAMI trial will open as a 
preliminary study to assess whether a sufficient number of eligible patients (n=50) can be identified who 
will accept a randomized intervention over a 15 months period2,5. This feasibility phase will inform the 
main trial that is powered using a 2% non-inferiority margin on a predicted 5-year LRR of 2.5% 
between BCS and mastectomy for all types of MIBC involving individual tumor foci up to 50mm2,5.   
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